Orna Therapeutics, Inc.

Orna Therapeutics, Inc. is a US-based biopharmaceutical company that focuses on developing innovative RNA therapeutics, particularly through engineered circular RNA technologies and advanced lipid nanoparticle delivery systems. Orna Therapeutics, Inc. , founded in 2019 in Cambridge, US, specializes in RNA therapeutic solutions.

The company has secured a total of 2 deals, with its most recent funding round being a Series B that raised USD 121. 00 mn on August 14, 2022, led by M Ventures. CEO Tom Barnes steers the organization, which has not indicated any parent or subsidiary structures. Orna Therapeutics specializes in the development of innovative RNA therapeutics, with core products centered around engineered circular RNA (oRNA®) and lipid nanoparticle (LNP) delivery systems.

These offerings target a wide array of diseases, with a focus on oncology, autoimmune diseases, and infectious diseases. The proprietary oRNA® technology enables enhanced protein expression and expanded delivery options beyond the liver, addressing conditions such as sickle-cell disease and beta-thalassemia. Their panCAR™ technology offers in vivo CAR modifications to immune cells, facilitating off-the-shelf treatment options without extensive pre-conditioning. The company collaborates with clients across the biopharmaceutical sector, emphasizing North America, Europe, and Asia-Pacific markets.

Orna Therapeutics generates revenue through strategic partnerships with major pharmaceutical companies, such as Merck, focusing on oncology and infectious disease therapies. Revenue streams derive from milestone payments, licensing agreements, and royalties related to their proprietary products. Clients typically engage in multi-year agreements involving shared development costs and revenue-sharing models, particularly for leading products like the CD19 panCAR program targeting B cell-driven autoimmune diseases. Specific pricing structures for these collaborations remain undisclosed due to the negotiation dynamics prevalent in the biotech industry.

In August 2022, Orna Therapeutics, Inc. raised USD 121. 00 mn in Series B funding led by Merck Ventures, aimed at advancing the development of its circular RNA and LNP delivery platform. The company intends to design and launch new products while expanding into new markets, particularly targeting enhanced presence within North America, Europe, and Asia-Pacific regions.

The recent funding will be utilized to support ongoing development efforts, ensuring the company remains at the forefront of RNA therapeutics.